Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 20;10(3):966-967.
doi: 10.1016/j.ekir.2024.12.018. eCollection 2025 Mar.

Sotagliflozin in Refractory Hypomagnesemia

Chintan V Shah  1
Affiliations

Sotagliflozin in Refractory Hypomagnesemia

Chintan V Shah. Kidney Int Rep. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Effect of sotagliflozin on serum magnesium levels in a patient with refractory hypomagnesemia. Serum Mg2+ levels significantly improved with sotagliflozin 200 mg daily compared with pre-sotagliflozin period (1.11 ± 0.09, n = 9 vs. 1.55 ± 0.13, n = 9; P ≤ 0.0001; 95% CI: −0.559 to −0.330). Note: The lowest serum Mg2+ levels per month were used for comparison. FEMg was calculated as 100 (uMg sCr)/(0.7 sMg uCr), where uMg and uCr represent urinary magnesium and creatinine concentrations measured in 24-h urine collections, respectively, and sMg and sCr represent serum magnesium and creatinine levels, respectively. CI, confidence interval; FEMg, factional excretion of magnesium; i.v. MgSO4, intravenous magnesium sulfate; NA, not available.
See this image and copyright information in PMC

References

    1. Shah C.V., Robbins T.S., Sparks M.A. Sodium-glucose cotransporter 2 inhibitors and management of refractory hypomagnesemia without overt urinary magnesium wasting: A report of 2 cases. Kidney Med. 2022;4 doi: 10.1016/j.xkme.2022.100533. - DOI - PMC - PubMed
    1. Shah C.V., Hammad N., Bhasin-Chhabra B., Rashidi A. SGLT2 inhibitors in management of severe hypomagnesemia in patients without diabetes: A report of 4 cases. Kidney Med. 2023;5 doi: 10.1016/j.xkme.2023.100697. - DOI - PMC - PubMed
    1. Armour S.L., Frueh A., Knudsen J.G. Sodium, glucose and dysregulated glucagon secretion: The potential of sodium glucose transporters. Front Pharmacol. 2022;13 doi: 10.3389/fphar.2022.837664. - DOI - PMC - PubMed
    1. Ray E.C., Boyd-Shiwarski C.R., Liu P., Novacic D., Cassiman D. SGLT2 inhibitors for treatment of refractory hypomagnesemia: A case report of 3 patients. Kidney Med. 2020;2:359–364. doi: 10.1016/j.xkme.2020.01.010. - DOI - PMC - PubMed
    1. Shah C.V., Sparks M.A., Lee C.T. Sodium/glucose cotransporter 2 inhibitors and magnesium homeostasis: A review. Am J Kidney Dis. 2024;83:648–658. doi: 10.1053/j.ajkd.2023.11.006. - DOI - PubMed

LinkOut - more resources